MX2015010296A - Tratamiento de formas progresivas de esclerosis multiple con laquinimod. - Google Patents

Tratamiento de formas progresivas de esclerosis multiple con laquinimod.

Info

Publication number
MX2015010296A
MX2015010296A MX2015010296A MX2015010296A MX2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A MX 2015010296 A MX2015010296 A MX 2015010296A
Authority
MX
Mexico
Prior art keywords
laquinimod
multiple sclerosis
human subject
treating
treatment
Prior art date
Application number
MX2015010296A
Other languages
English (en)
Inventor
Nora Tarcic
Dan Bar-Zohar
Liat Hayardeny
Yossi Gilgun Sherki
Tali Gorfine
Volker Knappertz
Ella Sorani
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015010296(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2015010296A publication Critical patent/MX2015010296A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)

Abstract

Esta invención proporciona un método para tratar a un sujeto humano afligido con una forma progresiva de esclerosis múltiple, que comprende administrar periódicamente al sujeto humano una cantidad de laquinimod efectiva para tratar al sujeto humano. Esta invención también proporciona laquinimod para utilizarse en el tratamiento de un sujeto humano afligido con una forma progresiva de esclerosis múltiple. Esta invención proporciona además las composiciones farmacéuticas y paquetes que comprenden una cantidad efectiva de laquinimod para tratar una forma progresiva de esclerosis múltiple.
MX2015010296A 2013-02-15 2014-02-13 Tratamiento de formas progresivas de esclerosis multiple con laquinimod. MX2015010296A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US201361911106P 2013-12-03 2013-12-03
PCT/US2014/016278 WO2014127139A1 (en) 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod

Publications (1)

Publication Number Publication Date
MX2015010296A true MX2015010296A (es) 2016-05-05

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010296A MX2015010296A (es) 2013-02-15 2014-02-13 Tratamiento de formas progresivas de esclerosis multiple con laquinimod.

Country Status (18)

Country Link
US (2) US20140235670A1 (es)
EP (1) EP2956137A4 (es)
JP (1) JP2016510343A (es)
KR (1) KR20150119227A (es)
CN (1) CN105163737A (es)
AU (1) AU2014216199A1 (es)
BR (1) BR112015019564A2 (es)
CA (1) CA2900503A1 (es)
CL (1) CL2015002181A1 (es)
EA (1) EA201591507A1 (es)
HK (2) HK1218254A1 (es)
IL (1) IL240014A0 (es)
MX (1) MX2015010296A (es)
PE (1) PE20151526A1 (es)
SG (1) SG11201505818WA (es)
TW (1) TW201442709A (es)
UY (1) UY35328A (es)
WO (1) WO2014127139A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
SG11201608674UA (en) * 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
JP6731915B2 (ja) 2014-10-16 2020-07-29 ノバルティス アーゲー 多発性硬化症治療用のシポニモドとラキニモドを含む組み合わせ
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
MX2019010174A (es) * 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
US20230296628A1 (en) * 2020-07-09 2023-09-21 Oklahoma Medical Research Foundation Biomarkers for Identifying Relapses in Multiple Sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
EA018031B1 (ru) * 2006-06-12 2013-05-30 Тева Фармасьютикал Индастриз, Лтд. Стабильные препараты лаквинимода
EP2567699A1 (en) * 2007-07-11 2013-03-13 MediciNova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
TW201438738A (zh) * 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010068867A1 (en) * 2008-12-11 2010-06-17 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
BR112012000568A2 (pt) * 2009-06-19 2015-10-06 Teva Pharma tratamento da esclerose múltipla com laquinimod
MX2013006464A (es) * 2010-12-07 2013-07-29 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple.
JP2014521659A (ja) * 2011-07-28 2014-08-28 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
PE20151435A1 (es) * 2012-10-12 2015-10-15 Teva Pharma Laquinimod para reducir el dano talamico en la esclerosis multiple
SG11201608674UA (en) * 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status

Also Published As

Publication number Publication date
HK1218254A1 (zh) 2017-02-10
HK1218251A1 (zh) 2017-02-10
CN105163737A (zh) 2015-12-16
EP2956137A4 (en) 2016-08-03
KR20150119227A (ko) 2015-10-23
UY35328A (es) 2014-09-30
US20180064702A1 (en) 2018-03-08
CL2015002181A1 (es) 2016-06-03
AU2014216199A1 (en) 2015-09-03
EA201591507A1 (ru) 2015-12-30
WO2014127139A1 (en) 2014-08-21
TW201442709A (zh) 2014-11-16
EP2956137A1 (en) 2015-12-23
US20140235670A1 (en) 2014-08-21
CA2900503A1 (en) 2014-08-21
SG11201505818WA (en) 2015-08-28
BR112015019564A2 (pt) 2017-07-18
PE20151526A1 (es) 2015-11-20
JP2016510343A (ja) 2016-04-07
IL240014A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
EA033374B9 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12012501741A1 (en) Treatment of lupus arthritis using laquinimod
MX367341B (es) Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
PH12012501740A1 (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
MX2015000398A (es) Formulaciones de laquinimod sin agente alcalinizante.
MX2016013944A (es) Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad.
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
GB201115977D0 (en) Neurodevelopmental disorders
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
MX2016001179A (es) Tratamiento de esclerosis multiple por induccion de alemtuzumab seguido por terapia de laquinimod.
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2016008214A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida.
AR094809A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod